Meiqi An, RN Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 9728 Winter Gardens Blvd, Lakeside, CA 92040 Phone: 619-938-0069 |
Christine Corado Holman, NURSE PRACTITIONER Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 10039 Vine St, Lakeside, CA 92040 Phone: 833-867-4642 |
Freshta Nejati, F.N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 10039 Vine St, Lakeside, CA 92040 Phone: 619-390-9975 |
News Archive
Venous thromboembolism, a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death.
"When children can tell their stories about a traumatic event in their own words or pictures and at their own speed, healing can begin," says Dr. Jodie Kliman, psychologist and professor at the Massachusetts School of Professional Psychology (MSPP) in Boston. That is why Kliman led MSPP's collaboration with the Children's Psychological Health Center (CPHC) in San Francisco and Ekol Akasya (Acacia School) in Haiti to create a workbook to facilitate that healing process in Haitian children and to identify those at greatest risk for long-term emotional problems.
According to the Centre for Disease Prevention and Control (CDC), cases of dangerous and rare Acute Flaccid Myelitis (AFM) are being noted across United States. This disease manifests similar to acute flaccid paralysis caused by polio virus say the experts. There is at present no treatment for this condition that primarily affects children and leads to paralysis of the limbs.
Induced pluripotent stem cells hold promise for regenerative medicine because they can, in theory, turn into any type of tissue and because they are made from a patient's own adult cells, guaranteeing compatibility. However, the technique that turns adult cells into these iPS cells is not foolproof; after reverting to their pluripotent state, these cells don't always correctly differentiate back into adult cells.
Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.
› Verified 4 days ago